Related Party

9 Months Ended

Sep. 30, 2012

Related Party Transactions [Abstract]

Related Party

2. Related Party

Based on its stock ownership in the Company, MD Anderson Cancer Center meets the criteria to be deemed a related party of Bio-Path Holdings. For the quarters ending September 30, 2012 and 2011, MD Anderson related party research and development expense was $47,582 and $50,000, respectively. MD Anderson related party research and development expense for the quarter ending September 30, 2012 consisted of $39,000 for expenses for treating Cohort 4 patients in the Company’s clinical trial and $8,582 for patent expenses. As of September 30, 2012, the Company had accrued expense of $39,000 for clinical trial expense for the related party, $8,582 in related party accounts payable and $50,000 in accrued license payments payable due to the related party for past patent expenses for the Company’s Technology License. See Notes 5 and 6. For the quarter ended September 30, 2011, the Company had $50,000 in R&D related party expense for clinical trial hospital expense, $100,000 in accrued expense related party for clinical trial hospital expense and $50,000 for accrued license payments related party for past patent expense for the Company’s Technology License.